Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A. Purim O, et al. Among authors: pelles avraham s. Target Oncol. 2018 Apr;13(2):217-226. doi: 10.1007/s11523-017-0548-8. Target Oncol. 2018. PMID: 29353436 Free PMC article.
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB. Safra T, et al. Among authors: pelles avraham s. Oncology. 2011;81(5-6):298-305. doi: 10.1159/000334456. Epub 2011 Dec 8. Oncology. 2011. PMID: 22156381 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F. Safra T, et al. Among authors: pelles avraham s. Mol Cancer Ther. 2011 Oct;10(10):2000-7. doi: 10.1158/1535-7163.MCT-11-0272. Epub 2011 Aug 11. Mol Cancer Ther. 2011. PMID: 21835933
The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX.
Barenboim A, Mercer D, Sahnan K, Gaffan A, Goren O, Halperin S, Brazowski E, Pelles Avraham S, Klausner JM, Lubezky N. Barenboim A, et al. Among authors: pelles avraham s. J Clin Med. 2024 Sep 2;13(17):5206. doi: 10.3390/jcm13175206. J Clin Med. 2024. PMID: 39274419 Free PMC article.
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption.
Geva R, Gusev A, Polyakov Y, Liram L, Rosolio O, Alexandru A, Genise N, Blatt M, Duchin Z, Waissengrin B, Mirelman D, Bukstein F, Blumenthal DT, Wolf I, Pelles-Avraham S, Schaffer T, Lavi LA, Micciancio D, Vaikuntanathan V, Badawi AA, Goldwasser S. Geva R, et al. Among authors: pelles avraham s. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2304415120. doi: 10.1073/pnas.2304415120. Epub 2023 Aug 7. Proc Natl Acad Sci U S A. 2023. PMID: 37549296 Free PMC article.